News Conference News NY Valves 2024 AV Block Common After Transcatheter Tricuspid Valve Replacement for TR Michael O'Riordan June 07, 2024
News Conference News VIVA 2023 ‘Dire’ Lack of Vascular Care in Underserved Areas Needs Creativity, Compassion L.A. McKeown November 03, 2023
News Conference News LINC 2023 What Works, What’s Noise? Novel Approaches Offer Hope in CLTI L.A. McKeown June 07, 2023
News Conference News ACC 2021 Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions L.A. McKeown May 21, 2021
News Conference News ACC 2020 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events L.A. McKeown March 28, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Conference News ESC 2019 Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS Michael O'Riordan September 01, 2019
News Conference News VIVA 2018 Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease L.A. McKeown November 15, 2018
News Conference News ESC 2018 ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More Shelley Wood August 20, 2018
News Conference News ACC 2018 My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up Shelley Wood March 27, 2018
News Conference News ISC 2018 COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke Todd Neale January 25, 2018
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2017 AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More Shelley Wood November 09, 2017
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017